CLINICAL SERVICES OVERVIEW

Similar documents
Innovative Products Available. OTC Products Available

Ambetter 90-Day-Supply Maintenance Drug List

PORTFOLIO Q October 2015 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/6

While there is around a 3% increase shown in costs for Category M lines, I think this is due to the inclusion of more lines in Category M.

BIOANALYTICAL ASSAY LIST

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 702 M %

WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract Research Organization

DT Description Price Category Price change Percentage BNF 1.2 Mebeverine 135mg tablets (100) 759 M %

COMMERCIAL APIs. S. No Molecule Name Therapeutic Category USDMF EDMF CEP IH

PORTFOLIO Q June 2014 Availability of products is subject to patent restrictions in countries where applicable patents are in effect 1/5

DT Description Price Category Price change Percentage

1. PROCEDURE FOR THIS INVITATION TO EOI 2. APIS INCLUDED IN THE 14TH INVITATION. Guidance Document 11 April 2017

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs

ASEBP and ARTA TARP Drugs and Reference Price by Categories

2019 Preventive medications and your plan

DT Description Price Category Price change

TennCare Program TN MAC Price Change List As of: 03/30/2017

Select Preventive Prescription Drugs Jan. 1, 2018

TN Cover Rx Tennessee CoverRx MAC Price Change List As of: 04/26/2018

Alaska Medicaid 90 Day** Generic Prescription Medication List

ANNOUNCEMENT. Dear Valued Customer:

Hospital Unit Dose Unit Dose Plus Liquid Unit Dose. BARCODE LISTING Spring See our new Barcode Scanning Guide on page 26

Orchid Chemicals & Pharmaceuticals Ltd. Orchid Towers 313, Valluvar Kottam High Road, Nungambakkam, Chennai , India. Tel : (91)

Glossary of Medications

The Gazette of the Democratic Socialist Republic of Sri Lanka

Product List Finished Dosage Forms (FDF) B2B Business

WEB ANNEX J. TABLE OF DRUG INTERACTIONS WITH ANTIRETROVIRAL DRUGS

Domperidone: Drug Interactions & Cautions (Mayo Clinic)

ANTIRETROVIRAL CONTRAINDICATIONS AND DRUG INTERACTIONS (Part 1 of 8) 10)

Hospital Unit Dose Unit Dose Plus BARCODE LISTING. Spring See our new Barcode Scanning Guide on page 30

Health Partners Medicare Prime and Value (2017) Updates

Update on the Medicines Patent Pool

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Riesbeck's Pharmacy Reward Club Generic Medication List February 2018 $4 30 Day Supply

PREZISTA. darunavir DATA SHEET

Alimentary Tract and Metabolism

Analyte(s) Therapeutic Method of Calibration Curve Biological Class Analysis Range Matrix

Rifamycins Drug interactions

Adnova Healthcare Pvt. Ltd. - Product List

Riesbeck's Pharmacy Reward Club Generic Medication List September 2017

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

2018 Step Therapy Criteria

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015

SOLID DOSAGE FORMULATIONS

MICROMEDEX(R) Healthcare Series Integrated Index

Therapeutic Drugs Monitoring TDM 2018 Therapeutic Drugs Monitoring Scheme Application Form

Riesbeck's Pharmacy Reward Club Generic Medication List October 2017

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

CURRICULUM VITAE. TAAB Biostudy Services, 76/D, Ibrahimpur Road, Kolkata

J Jubilant Pharma Group, catering to Dosage

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs

BULLETIN # 84. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 22, 2015

Monographs on ARV and hepatitis medicines in The International Pharmacopoeia

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

2019 Preventive Drug List

ATYPICAL ANTIPSYCHOTICS

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

STEP THERAPY PROGRAM

Elbasvir and Grazoprevir. (Systemic) Uses. Dosage and Administration

Centurion Laboratories Pvt. Ltd.

BULLETIN # 102. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on January 24, 2019

Therapeutic Drugs Monitoring TDM 2016 Therapeutic Drugs Monitoring Scheme Application Form

Unit - IV API's & Intermediates Vizag, A.P., India.

Clinical Pharmacology of Integrase Inhibitors

The Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England

PREZISTA Tablets darunavir (da-roo-nuh-veer) Consumer Medicine Information

Orodispersible tablets & Tablets

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml

2018 PDP Premier Step Therapy Document September 2018 Y0114_18_33144_I_009

Pharma X Consultancy Inc. Inventory List

Supporting Evidence Document for the BCPRA CNI protocol for MN

ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS

Our Values. Quality Intelligent efforts in everyday practice. Innovation Change that unlocks new value. Performance Passion for results

6 Each Film coated Tablet Contains :- Ofloxacin 200 mg 10 x 10 Alu

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

Generic Medications 2,500 + available Call or MEDSerivces for medications not listed.

Education. Current Activities

Calgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015

BULLETIN # 101. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 18, 2018

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT

New York State HCV Provider Webinar Series. Drug-Drug Interactions Including PPIs

SUMMARY OF PRODUCT CHARACTERISTICS. Excipient with known effect: Darunavir Alvogen 400 mg: Each tablet contains mg sunset yellow FCF (E110).

PREZISTA Tablets darunavir (da-roo-nuh-veer) Consumer Medicine Information

Health Partners Medicare Prime and Value (2017) Updates

Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference.

AMANTADINE 50 MG/5 ML SYRUP ACYCLOVIR 200 MG CAPSULES ACYCLOVIR 400 MG TABLETS ACYCLOVIR 800 MG TABLETS 30 90

(To be Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

The use of Saliva instead of Plasma as a Surrogate in Drug Bioavailability and Bioequivalence Studies in Humans

12/9/2015. Drug Interactions. Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc.

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

about us Cyndea Pharma independent

Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data

REGULATORY ASSESSMENT OF CRITICAL DOSE DRUGS / NARROW THERAPEUTIC RANGE DRUGS IN HONG KONG

1. Procedure for this Invitation to EOI. 2. Medicinal products included on the 14 th Invitation. Guidance Document 14 May 2016

Chapter / Section / Drug

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

Table 1. Testing set of CYP3A4 inhibitors (120 compounds).

Formulary for the JHM Outpatient Medication Assistance Program (OMAP)

Transcription:

CLINICAL SERVICES OVERVIEW Aizant Drug Research Solutions Pvt. Ltd. Sy. No. 172 & 173, Apparel Park Road, Dulapally, Hyderabad- 500 100, INDIA. Phone: +91 40 2379 2190/91/92: Fax: +91 40 2379 2223 E. Mail: sri.s@aizant.com Web: www.aizant.com

1.0 Introduction Aizant Drug Research Solutions is a pharmaceutical contract research organization (CRO), which provides integrated drug development solutions with a diverse portfolio of services catering to the pharmaceutical companies globally. Aizant is founded by Dr. Varma Rudraraju, PhD (USA), a pharmaceutical professional with over 25 years of work experience in the USA and five years in India. His last assignment in USA was as Director of Formulation and Development at Hoffmann La Roche. Aizant s core management team comprises professionals with experience in pharmaceutical industries across the world (USA/India/Europe/Australia). Aizant provides end-to-end pharmaceutical development services. The core competencies include Pharmaceutical dosage form development Contract Manufacturing services Stability testing and Microbiology testing services Clinical Development services including Clinical and Bioanalytical Research Aizant offers a diverse portfolio of capabilities partnering with health care companies specializing in new molecular entities (NME s), generics (ANDA s) and over the counter (OTC s) products-globally. 2.0 Clinical Facility Aizant has a fully equipped clinical facility to conduct studies as per regulatory requirements. 80 beds (2 Clinics of 40 bed each) Facility spread in 28,000 Sq. ft. area Dedicated registration area In-house diagnostic laboratory Well equipped ICU s, Bed lift and a ramp with in-house Ambulance IP based cameras to virtually monitor projects Part of Volunteer Cross Participation Verification Scheme (VCPVS) Archival (equipped with CO2 flooding system) Has conducted 600+ clinical studies Customers originate from USA, Europe, Canada, SA, Brazil & India Can handle various dosage forms including solid orals, sub-linguals, orally disintegrating tablets, parenterals, pessaries and suppositories

3.0 Bioanalytical Facility Aizant s bioanalytical facility has 10 LC-MS/MS including a state of art high end API 5500 where method sensitivity required Facility spread in 7,000 Sq. ft. area More than 250 validated methods Capable to deal with complex methods such as Paricalcitol, Ursodiol, Ethinyl Estradiol, Nicotin Excellent tie-up with animal facilities to offer one stop solution for preclinical needs Range of equipment and instruments to support sample processing 4.0 Regulatory Approvals S. NO. REGULATORY AGENCY INSPECTION DATE(S) INSPECTION AREA OUTCOME 1. DCG(I) 17 APR 2008 FACILITY INSPECTION 2. DCG(I) 3. USFDA 4. NABL (ISO 15189:2007) 22 MAR 2010 AND 23 MAR 2010 (RENEWAL AUDIT) FACILITY INSPECTION 12 APR 2010 TO 16 APR 2010 CLINICAL PHASE OF STUDY 08 MAY 2010 AND 09 MAY 2010 DIAGNOSTIC FACILITY 5. ANVISA 12 JUL 2010 TO 16 JUL 2010 FACILITY INSPECTION 6. WHO 20 OCT 2011 AND 21 OCT 2011 7. 8. TURKEY (MOH) NABL (ISO 15189:2007) CLINICAL PHASE OF STUDY 20 DEC 2011 AND 21 DEC 2011 FACILITY INSPECTION 03 MAR 2012 AND 04 MAR 2012 (RENEWAL AUDIT) DIAGNOSTIC FACILITY 9. ISO 9001:2008 10 DEC 2012 TO 12 DEC 2012 FACILITY INSPECTION 10. USFDA 10 JUN 2013 TO 14 JUN 2013 (SECOND AUDIT) 11. ANSM (FRANCE) 07 OCT 2013 TO 09 OCT 2013 12. ISO 9001:2008 13. NABL (ISO 15189:2012) 14. DCG(I) 15. ISO 9001:2008 08 NOV 2013 (SURVEILLANCE AUDIT) 05 APR 2014 AND 06 APR 2014 (RENEWAL AUDIT) 02 JUN 2014 AND 03 JUN 2014 (RENEWAL AUDIT) 26 DEC 2014 (SECOND SURVEILLANCE AUDIT) ALL PHASES OF STUDY CLINICAL PHASE OF STUDY FACILITY INSPECTION DIAGNOSTIC FACILITY FACILITY INSPECTION FACILITY INSPECTION 16. ANVISA 25 FEB 2015 TO 27 FEB 2015 ALL PHASES OF STUDY 17. WHO 23 MAR 2015 TO 25 MAR 2015 ALL PHASES OF STUDY

18. UK-MHRA 26 OCT 2015 TO 30 OCT 2015 19. ISO 9001:2008 20. USFDA 21. USFDA 28 JAN2016 AND 29 JAN 2016 (RECERTIFICATION AUDIT) 16 AUG 2016 TO 26 AUG 2016 (THIRD AUDIT) 17 OCT 2016 TO 21 OCT 2016 (SECOND AUDIT) 5.0 Clinical Development Services FACILITIES (GCP/GLP) INSPECTION AND ALL PHASES OF THE SELECTED STUDIES FACILITY INSPECTION CLINICAL PHASE OF STUDY BIO-ANALYTICAL PHASE OF STUDY Aizant offers following clinical services: Bioavailability & Bioequivalence Studies Steady State Pharmacokinetics & Pharmacodynamics Studies Patient PK Studies Clinical End-Point Studies Method Development and Validations for New chemical entities Bioanalysis of samples Biostatistics (Phoenix & SAS) Clinical study monitoring Studies in Special Population (geriatric, postmenopausal etc) Vaccine Studies Therapeutic Peptides and Protein Analysis

6.0 List of Validated Methods Name of the Compound Matrix Anti-Coagulant Equipment Linearity Range Abacavir + Lamivudine Abacavir * + Lamivudine * (Very high Sensitive) Abacavir * + Lamivudine * (Extended Linearity) Human Plasma K2 EDTA & K3 EDTA Premier XE Human Plasma K3 EDTA API-4000 Human Plasma K3 EDTA API-4000 25 ng/ml 6000 ng/ml 10 ng/ml 2400 ng/ml 5 ng/ml 4000 ng/ml 2.5 ng/ml 2000 ng/ml 50 ng/ml 15000 ng/ml 20 ng/ml 6000 ng/ml Abiraterone * 0.2 ng/ml - 150 ng/ml Acomprosate * Human Plasma K2 EDTA API-3200 5 ng/ml 1000 ng/ml Aceclofenac Human Plasma K2 EDTA API-3200 0.1 µg/ml - 50µg/mL Acetazolamide * 60 ng/ml 25000 ng/ml Albuterol * Human Plasma K2 EDTA Premier XE 0.1 ng/ml 30 ng/ml Amoxicillin + Clavulanic Acid $ 66 ng/ml 21500 ng/ml 40 ng/ml 12850 ng/ml Apixaban * Human Plasma K2 EDTA API-3200 2 ng/ml - 1200 ng/ml Aprepitant Human Plasma K2 EDTA Premier XE 10 ng/ml 5000 ng/ml Armodafinil* Human Plasma K2 EDTA API-3200 25 ng/ml 10000 ng/ml Artemether & Dihydroartemisinin Aspirin* + Salicylic Acid *$ Atorvastatin* + o-hydroxy Atorvastatin* + p-hydroxy Atorvastatin* Human Plasma K3 EDTA API-5500 1.0 ng/ml 500 ng/ml Human Plasma Sod. Fluoride API-4000 15 ng/ml 4050 ng/ml 80 ng/ml 20000 ng/ml 200 pg/ml 200000 pg/ml 200 pg/ml 200000 pg/ml 200 pg/ml 200000 pg/ml Azelnidipine + Olmesartan * 1 ng/ml 40 ng/ml & 3.0 ng/ml 1200 ng/ml Bupropion 1.5 ng/ml 500 ng/ml Bupropion* + 1.7 ng/ml 500 ng/ml Hydroxy Bupropion 10 ng/ml 3000 ng/ml

Bupropion* + Hydroxy Bupropion + Erythro Bupropion* + Threo Bupropion* 1 ng/ml 600 ng/ml 2.5 ng/ml 1500 ng/ml 2 ng/ml 1200 ng/ml 2 ng/ml 1200 ng/ml Cefixime 20 ng/ml 10000 ng/ml Cefpodoxime * Human Plasma K2 EDTA Premier XE 40 ng/ml 8000 ng/ml Celecoxib * Human Plasma K2 EDTA Premier XE 10 ng/ml 3000 ng/ml Celecoxib * Human Plasma K2 EDTA Premier XE 5 ng/ml 3000 ng/ml Choline Fenofibrate (as Fenofibric acid)* Carbamazepine + Oxcarbamazepine + 10-Hydroxy Oxcarbazepine Human Plasma K2 EDTA Premier XE 80 ng/ml 20000 ng/ml Human Plasma K2 EDTA Premier XE 12 ng/ml 6000 ng/ml 10 ng/ml 5000 ng/ml 25 ng/ml 12500 ng/ml Cilostazole Human Plasma K2 EDTA Premier XE 5 ng/ml 2000 ng/ml Cinacalcet * Human Plasma K2 EDTA Premier XE 02 ng/ml 80 ng/ml Clarithromycin Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Clarithromycin + 14-Hydroxy Clarithromycin Human Plasma K2 EDTA & K3 EDTA Premier XE 10 ng/ml 4000 ng/ml 5 ng/ml - 2000 ng/ml Clobazam * 1 ng/ml 1000 ng/ml Clonazepam * Human Plasma K2 EDTA API-5500 100 pg/ml 50000 pg/ml Clopidogrel * Human Plasma K2 EDTA Premier XE 0.1 ng/ml 6000 ng/ml Cycloserine * 200 ng/ml 40000ng/mL Dapsone * Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Deferasirox Human Plasma K2 & K3 EDTA API-3200 0.1µg/mL 50µg/mL Des loratidine + 3-OH-Des loratidine * Desogestrel* $ (as 3-Keto desogestrel) 50 pg/ml - 10000 pg/ml for both Human Plasma K2 EDTA API-5500 20 pg/ml 10 ng/ml Dexamethasone * Human Plasma K2 EDTA API-3200 0.7ng/mL to 80 ng/ml Diclofenac Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Dienogest $ 1 ng/ml 200 ng/ml Dienogest (Sensitive Method) * $ 0.8 ng/ml 200ng/mL Diltiazem Human Plasma K2 EDTA Premier XE 1 ng/ml 700 ng/ml Diltiazem Human Plasma K2 EDTA Premier XE 0.6 ng/ml 600 ng/ml

N-Desmethyldiltiazem Desacetyldiltiazem * 0.3 ng/ml 300 ng/ml 0.3ng/mL 300 ng/ml Dipyridamole * Human Plasma K2 EDTA Premier XE 20 ng/ml 10000 ng/ml Doxicycline Human Plasma K2 EDTA Premier XE 10 ng/ml 2000 ng/ml Drospirenone * $ Human Plasma K2 EDTA Premier XE 1 ng/ml 200 ng/ml Efavirenz * Human Plasma K2 EDTA Premier XE 60 ng/ml 18000 ng/ml Entacavir * Human Plasma K2 EDTA API-5500 50 pg/ml 20000 pg/ml Eplerenone * 10 ng/ml 6000 ng/ml Eslicarbazepine * Human Plasma K3 EDTA API-4000 50 ng/ml 30000 ng/ml Esomeprazole Human Plasma K2 EDTA API-3200 10 ng/ml 6440 ng/ml Ethinyl Estradiol* $ 5 pg/ml 500 pg/ml Ethinyl Estradiol* $ (Sensitive) 3 pg/ml 600 pg/ml Etodolac * 0.2 µg/ml - 80 µg/ml Everolimus 0.200 ng/ml 100 ng/ml Exemestane * $ 0.1 ng/ml 40 ng/ml Ezetimib + Ezetimibe phenoxy β-d-glucuronide * $ 0.1 ng/ml 20 ng/ml & 1 ng/ml 200 ng/ml Febuxostat * Human Plasma K2 EDTA Premier XE 25 ng/ml 7000 ng/ml Felbamate * Human Plasma K2 EDTA API-3200 0.2µg/mL 80µg/mL Felodipine * 0.2 ng/ml 20 ng/ml Fenofibric acid * Human Plasma K2 EDTA Premier XE 80 ng/ml 20000 ng/ml Fingolimod * $ Whole Blood K2 EDTA API-4000 50 pg/ml 5000 pg/ml Fosamprenavir (as Amprenavir)* Fosamprenavir (as Amprenavir)* Sensitive method Human Plasma K2 EDTA Premier XE 40 ng/ml 16 µg/ml Human Plasma K2 EDTA Premier XE 20 ng/ml 10 µg/ml Gabapentin 20 ng/ml 15 µg /ml Gestodene Human Plasma K2 EDTA API-5500 50 pg/ml 6200 pg/ml Gliclazide * Human Plasma K2 EDTA Premier XE 20 ng/ml 6000 ng/ml Gliclazide * Human Plasma K3 EDTA API-4000 10 ng/ml 6000 ng/ml Glipzide * Human Plasma K2 EDTA API-3200 3 ng/ml 1500 ng/ml Glimepride * 3 ng/ml 1500 ng/ml Hydroxazine * Human Plasma K2 EDTA API-3200 0.5 ng/ml 150 ng/ml

Ibuprofen* Human Plasma K2 EDTA Premier XE 0.2 µg/ml 120 µg/ml Isoniazide * Human Plasma K3 EDTA API-4000 50ng/mL 15000 ng/ml Irbesartan * 10 ng/ml - 8000 ng/ml Ketoconazole * 50ng/mL 8000 ng/ml Lamivudine Human Plasma K2 EDTA Premier XE 25 ng/ml 5000 ng/ml Lansoprazole Human Plasma K2 EDTA Premier XE 5 ng/ml 5000 ng/ml Lacosamide * Human Plasma K2 EDTA Premier XE 75 ng/ml 25000 ng/ml Levodopa Carbidopa * 5 ng/ml 3000 ng/ml 1 ng/ml 600 ng/ml Levocitirizine 1 ng/ml 600 ng/ml Levonorgestrel * $ 100 ng/ml 3500 ng/ml Linezolide * Human Plasma K2 EDTA API-3200 0.150 µg/ml 50 µg/ml Lopinavir + Ritonavir * Human Plasma K3 EDTA Premier XE 40 ng/ml 12000 ng/ml & 2 ng/ml 600 ng/ml Lumefantrine * Human Plasma K3 EDTA Premier XE 0.1 µg/ml 20 µg/ml Mesalamine * 25 ng/ml 3000 ng/ml Meloxicam 5 ng/ml - 2000 ng/ml Metoprolol* 0.2 ng/ml 200 ng/ml & K3 EDTA Metoprolol Human Plasma K2 EDTA Premier XE 1.5 ng/ml 535 ng/ml Metaxalone * Human Plasma K2 EDTA Premier XE 20 ng/ml 15000 ng/ml Metformin + Gliclazide * Human Plasma K2 EDTA Premier XE 20 ng/ml - 6000 ng/ml Methocabomol Human Plasma K2 EDTA Premier XE Methocabomol * 100 ng/ml 15000 ng/ml 100 ng/ml 40000 ng/ml Modafinil * 50 ng/ml 20000 ng/ml Mono Methyl Fumarate * $ Human Plasma K2 EDTA API-3200 10 ng/ml 4000 ng/ml Mono Methyl Fumarate * $ (Short Run Time) Human Plasma K2 EDTA API-3200 10 ng/ml 4000 ng/ml Montelukast * Human Plasma K2 EDTA Premier XE 1 ng/ml 1000 ng/ml Moxifloxacin * Human Plasma K2 EDTA Premier XE 30 ng/ml 6000 ng/ml Naproxen * Human Plasma K2 EDTA Premier XE 1 µg/ml 200 µg/ml Nicotine * $ Human Plasma K2 EDTA API-5500 0.1 ng/ml 30 ng/ml Nifedipine Human Plasma K2 EDTA Premier XE 500 ng/ml 250000 ng/ml Nitrofurantoin * Human Plasma K2 EDTA API-3200 5 ng/ml 2000 ng/ml

Nitrofurantoin (Sensitive)* Human Plasma K2 EDTA API-3200 1 ng/ml 1500 ng/ml Norethindrone * $ Human Plasma K2 EDTA API-5500 100 50000 pg/ml Norgestrel $ Human Plasma K2 EDTA & K3 EDTA API-4000 300 pg/ml 50 ng/ml Olmesartan * 10 ng/ml 4000 ng/ml Olmesartan* + Amlodipine* 5 ng/ml 2200 ng/ml 50 pg/ml 22000 pg/ml Omeprazole Human Plasma K2 EDTA Premier XE 5 ng/ml 4000 ng/ ml Ondansetron * 200 pg/ml 100 ng/ml Pantoprazole Human Plasma K2 EDTA API-3200 30 ng/ml 7500 ng/ml Paricalcitol* $ Human Plasma K2 EDTA API-5500 5 pg/ml 1000 pg/ml Paricalcitol* $ Rat Plasma K2 EDTA API-5500 20 pg/ml 40000 pg/ml Paroxetine 200 pg/ml 50000 pg/ml Penciclovir Human Plasma K2 EDTA API-3200 10 ng/ml 5000 ng/ml Pitavastatin + Pitavastatin Lactone* 500 pg/ml 400 ng/ml 500 pg/ml 400 ng/ml Posaconazole * Human Plasma K3 EDTA API-3200 4 ng/ml 2200 ng/ml Prazequatel * Human Plasma K2 EDTA API-3200 5 ng/ml 2500 ng/ml Prednisolone * Human Plasma K2 EDTA Premier XE 3 ng/ml 1050 ng/ml Propranolol+ 4-Hydroxy Propranolol * $ Human Plasma K2 EDTA Premier XE Propafenone * $ + 5-Hydoxy Propafenone* Prothionamide* + Prothionamide Sulphoxide Human Plasma K3 EDTA Premier XE 1.5 ng/ml 700 ng/ml 1.2 ng/ml 550 ng/ml 1 ng/ml 500 ng/ml 1 ng/ml 500 ng/ml 30ng/mL 4000ng/mL + 50ng/mL 6600ng/mL Pyridostigmine $ 0.5 ng/ml 125 ng/ml Quetiapine * Human Plasma K2 EDTA Premier XE 1 ng/ml 1500 ng/ml Ranolazine * Human Plasma K2 EDTA Premier XE 5 ng/ml 4000 ng/ml Rasagiline * 30 pg/ml 12000 pg/ml Rosuvastatin * 0.2 ng/ml 200 ng/ml Risedronic Acid * $ Human Plasma K2 EDTA API-5500 50 pg/ml 80000 pg/ml Risedronic Acid Extended Linearity * $ 0.250 ng/ml 500 ng/ml Rivaroxaban * Human Plasma K2 EDTA API-3200 1 ng/ml 430 ng/ml

Rivaroxaban Extended Linearity * 1 ng/ml 600 ng/ml Rizatriptan * 0.2 ng/ml 80 ng/ml Scenidazole Human Plasma K2 EDTA Premier XE 0.2 µg/ml 40 µg/ml Sertraline 0.5 ng/ml 100 ng/ml Simvastatin + Simvastatin Acid * $ Human Plasma K2 EDTA API-5500 0.200 ng/ml 100 ng/ml (For both) Sirolimus Human Whole Blood K2 EDTA API-4000 0.2 ng/ml 100 ng/ml Sulphomathoxazole + Trimethoprime Human Plasma K3 EDTA API-4000 1µg/mL 120µg/mL + 30 ng/ml -3600 ng/ml Tadalafil * Human Plasma K2 EDTA Premier XE 0.2 ng/ml 1000 ng/ml Tenofovir * + Emtricitabine * Human Plasma K2 EDTA Premier XE 8 ng/ml 2000 ng/ml 16 ng/ml 4000 ng/ml Tacrolimus Human Whole Blood Telmisartan* + HCTZ* K2 EDTA Premier XE 0.5 ng/ml 100 ng/ml 1.0 ng/l 150 ng/ml 1.0 ng/ml 1200 ng/ml Teriflunamide * Human Plasma K2 EDTA API-3200 10 ng/ml 4000 ng/ml Tolterodine * Human Plasma K2 EDTA Premier XE 10 pg/ml 3500 pg/ml Tolterodine +5 OH Tolterodine *$ Trandalopril *+ Trandaloprilate * 30 pg/ml to 10000 pg/ml 0.2 ng/ml 80 ng/ml + 0.3 ng/ml 120 ng/ml Tranylcypromine * $ 0.7 ng/ml 140 ng/ml Urapidil Human Plasma K2 EDTA Premier XE 5 ng/ml 1500 ng/ml Ursodeoxycholic acid Glycodeoxycholic acid Human Plasma Na. Heparin API-4000 Taurodeoxycholic acid * $ 10 ng/ml 9060 ng/ml 10 ng/ml 9300 ng/ml 5 ng/ml 300 ng/ml Valproic acid Human Plasma K2 EDTA API-3200 0.5 µg/ml 150 µg/ml Valsartan * Human Plasma K2 EDTA Premier XE 50 ng/ml 15000 ng/ml Valsartan + HCTZ * 30 ng/ml 15000 ng/ml 1 ng/ml 500 ng/ml Verapamil * + Nor Verapamil * 1.5 ng/ml 600 ng/ml for both

Zileuton * Human Plasma K2 EDTA Premier XE 50 ng/ml 10000 ng/ml Ziprasidone * Human Plasma K2 EDTA Premier XE 1 ng/ml 200 ng/ml *: Labeled Internal Standard; $: Premium method

7.0 List of Methods Ready for Validation Name of the Compound Matrix Anti-Coagulant Equipment Linearity Range Agomelatine Human Plasma K3 EDTA API-4000 0.030 ng/ml 25 ng/ml Aripiprazole Human Plasma K3 EDTA PREMIER XE 0.300 ng/ml 100 ng/ml Atazanavir + Ritonavir Human Plasma K3 EDTA API-3200 10 ng/ml 8000 ng/ml &5 ng/ml 4000 ng/ml Bromocriptine Human Plasma K2 EDTA API-5500 1 pg/ml 500 pg/ml Cefdinir 30 ng/ml 9000 ng/ml Canagliflozin Human Plasma K3 EDTA API-4000 10 ng/ml 7500 ng/ml Dabigatran 1 ng/ml 500 ng/ml Darunavir + Cobicistat Human Plasma K3 EDTA API-4000 150 ng/ml 15000 ng/ml + 20ng/mL 2000ng/mL Deslansoprazole Human Plasma K2 EDTA Premier XE 10 ng/ml 400 ng/ml Dolutegravir Human Plasma K3 EDTA API-4000 20 ng/ml 7000 ng/ml Drospirenone Sensitive 0.5 ng/ml 100 ng/ml Total Dabigatran 1 ng/ml 500 ng/ml Efavirenz (Sensitive) Human Plasma K3 EDTA Premier XE 5.0 ng/ml 1500 ng/ml Ethinyl Estradiol (Sensitive) Fingolimod Phosphate Human Plasma K2 EDTA API-5500 1 pg/ml 200pg/mL Human Whole Blood K2 EDTA API-5500 50 pg/ml 5000 pg/ml Ivacaftor Dog Plasma K2 EDTA API-3200 20 ng/ml 8000 ng/ml Lamivudine + Stavudine Human Plasma K2 EDTA Premier XE 25 ng/ml 5010 ng/ml Lamotrigine 1 ng/ml to 750 ng/ml Lopinavor + Ritonovir 1 ng/ml to 600 + (Sensitive Method) 0.1 ng/ml to 60ng/mL Meclizine Human Plasma K2 EDTA Premier XE 0.5 ng/ml 300 ng/ml Medroxy Progesterone Human Plasma K2 EDTA API-5500 25 pg/ml 10000 pg/ml Mesalamine (Extended Linearity) Human Plasma K3 EDTA API-4000 4 ng/ml 3000 ng/ml Metformin Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Omeprazole (without buffer) cis-phytonadion & trans-phytonadion Human Plasma K3 EDTA Premier XE 5 ng/ml 4000 ng/ml Human Plasma K3 EDTA API-4000 0.1 ng/ml to 100 ng/ml

Name of the Compound Matrix Anti-Coagulant Equipment Linearity Range Pramipexole 20 pg/ml 4000 pg/ml Rabeprazole Human Plasma K2 EDTA Premier XE 3 ng/ml 1500 ng/ml Raltegravir Human Plasma K3 EDTA Premier XE 15 ng/ml 15000 ng/ml Ritonavir Human Plasma K2 EDTA Premier XE 10 ng/ml 2000 ng/ml Ritonavir (Sensitive) Human Plasma K3 EDTA API-4000 5 ng/ml 5000 ng/ml Testosterone Dog Serum N/A API-5500 0.500 ng/ml 500 ng/ml Tenofovir (Sensitive) + Emtricitabine Human Plasma K3 EDTA API-4000 2.0 ng/ml 250 ng/ml 20 ng/ml 2500 ng/ml Thiotropium Human Plasma K2 EDTA API-5500 0.500 pg/ml 500 pg/ml Traimcinolone Dog Plasma K2 EDTA API-5500 20 pg/ml 5000 pg/ml

8.0 List of Method Under Development Name of the Compound Matrix Anti-Coagulant Amlodipine + Irbesartan Human Plasma K2 EDTA Anagrelide Human Plasma K2 EDTA Atazanavir + Ritonavir Human Plasma K3 EDTA Aripiprazole Human Plasma K2 EDTA Azelnidipine + Olmesartan Human Plasma K2 EDTA Apremilast Rat Plasma K2 EDTA Asenapine Human Plasma K2 EDTA Azathioprine Human Plasma K2 EDTA Cefuroxime Human Plasma K2 EDTA Clopidogrel + Clopidogrel Acid Human Plasma K2 EDTA Cobicistat + Elvitegravir Human Plasma K3 EDTA Dalfampridine Human Plasma K2 EDTA Dapoxetine Human Plasma K2 EDTA Desmopressin Human Plasma K2 EDTA Dolutegravir + Darunavir + Ritonavir Human Plasma K3 EDTA Dutasteride Human Plasma K2 EDTA Elitriptan Human Plasma K2 EDTA Empagliflozin Human Plasma K2 EDTA Enalapril + Enalaprilate Human Plasma K2 EDTA Entacapone Human Plasma K2 EDTA Estradiol Human Plasma K2 EDTA Fingolimod Phosphate Human Whole Blood K2 EDTA Fludrocortisone Human Plasma K2 EDTA Hydrocortisone Human Plasma K2 EDTA Lacidipine Human Plasma K2 EDTA Levomefolate Human Plasma K2 EDTA Levothyronine (T3) Human Plasma K2 EDTA Linagliptin Human Plasma K2 EDTA Lopinavir + Ritonavir (Sensitive Method) Human Plasma K3 EDTA Methyl Prednisolone Human Plasma K2 EDTA Nadalol Human Plasma K2 EDTA Prasugrel Human Plasma K2 EDTA Pristinamycin I &II Human Plasma K2 EDTA Sofosbuvir Human Plasma K3 EDTA Tamsulosin Human Plasma K2 EDTA Tenofovir Alfenamide Human Plasma K3 EDTA

Name of the Compound Matrix Anti-Coagulant Amlodipine + Irbesartan Human Plasma K2 EDTA Valgancyclovir + Gancyclovir Human Plasma K2 EDTA